Payment overview · 2025
General Payments
$99.18
6 reported records · 5 companies
Healthcare provider profile · identity verified
Heather Cannon, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PHILADELPHIA, MS · NPI 1801082409
Verified facts
What the public records show
CMS Open Payments records show Heather Cannon, M.D. received $99.18 in general payments during 2025 across 6 reported records.
PFIZER INC. accounted for 31.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Farxiga by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.09 | 31.4% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.10 | 22.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.02 | 17.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $14.98 | 15.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $13.99 | 14.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $99.18 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.09 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.10 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $17.02 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $13.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 55 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 73 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 46 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
73 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
104 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 355 | 100 |
| Levothyroxine Sodium | Levothyroxine Sodium | 313 | 78 |
| Amlodipine Besylate | Amlodipine Besylate | 288 | 81 |
| Potassium Chloride | Potassium Chloride | 267 | 72 |
| Furosemide | Furosemide | 258 | 75 |
| Atorvastatin Calcium | Atorvastatin Calcium | 244 | 73 |
| Gabapentin | Gabapentin | 238 | 52 |
| Metformin Hcl | Metformin Hcl | 226 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 207 | 54 |
| Losartan Potassium | Losartan Potassium | 193 | 48 |
| Lisinopril | Lisinopril | 186 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 182 | 56 |
| Meloxicam | Meloxicam | 146 | 53 |
| Montelukast Sodium | Montelukast Sodium | 145 | 43 |
| Pantoprazole Sodium | Pantoprazole Sodium | 141 | 42 |
| Ozempic | Semaglutide | 139 | 27 |
| Sertraline Hcl | Sertraline Hcl | 130 | 31 |
| Trazodone Hcl | Trazodone Hcl | 124 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 119 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 114 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 110 | 31 |
| Jardiance | Empagliflozin | 104 | 26 |
| Carvedilol | Carvedilol | 100 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 98 | 24 |
| Tradjenta | Linagliptin | 92 | 17 |
| Allopurinol | Allopurinol | 87 | 24 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 82 | 25 |
| Glipizide | Glipizide | 78 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 78 | 19 |
| Pravastatin Sodium | Pravastatin Sodium | 77 | 19 |
| Farxiga | Dapagliflozin Propanediol | 73 | 17 |
| Clonazepam | Clonazepam | 69 | 11 |
| Celecoxib | Celecoxib | 66 | 20 |
| Amitriptyline Hcl | Amitriptyline Hcl | 64 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 64 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 62 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 62 | 16 |
| Temazepam | Temazepam | 62 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 61 | 13 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 16 |
| Lovastatin | Lovastatin | 56 | 17 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 13 |
| Eliquis | Apixaban | 55 | 14 |
| Simvastatin | Simvastatin | 54 | 16 |
| Valsartan | Valsartan | 53 | 12 |
| Meclizine Hcl | Meclizine Hcl | 52 | 21 |
| Metformin Hcl Er | Metformin Hcl | 51 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 48 | 23 |
| Lorazepam | Lorazepam | 48 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 47 | 15 |
| Mounjaro | Tirzepatide | 46 | suppressed |
| Mirtazapine | Mirtazapine | 45 | suppressed |
| Spironolactone | Spironolactone | 45 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | 11 |
| Cilostazol | Cilostazol | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 44 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Linzess | Linaclotide | 43 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 42 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 39 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 38 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 32 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | 11 |
| Clonidine Hcl | Clonidine Hcl | 36 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Ibuprofen | Ibuprofen | 33 | 11 |
| Glipizide Er | Glipizide | 31 | suppressed |
| Methocarbamol | Methocarbamol | 31 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 20 |
| Alendronate Sodium | Alendronate Sodium | 28 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Azithromycin | Azithromycin | 26 | 22 |
| Movantik | Naloxegol Oxalate | 26 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 20 |
| Estradiol | Estradiol | 25 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 24 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Probenecid | Probenecid | 23 | suppressed |
| Nystatin | Nystatin | 22 | 13 |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Atenolol | Atenolol | 19 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Glimepiride | Glimepiride | 17 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Myrbetriq | Mirabegron | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Methotrexate | Methotrexate Sodium | 16 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Phenobarbital | Phenobarbital | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Irbesartan | Irbesartan | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Alprazolam | Alprazolam | 14 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | 12 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Praluent Pen | Alirocumab | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Leflunomide | Leflunomide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $99.18 · 6 records | PFIZER INC. | ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, MOUNJARO, NURTEC ODT, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error